RxDoctor Payments Data

Won Kim, MD

Ophthalmology · Chevy Chase, MDNPI 1366536153

Payments from drug & device makers

$8,336in general payments, 2019–2025

Across 172 payments — averaging $48.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Alcon$2K
  • NEW World Medical,inc.$587
  • Sight Sciences, Inc.$542
  • Sun Pharmaceutical Industries Inc.$458
  • Glaukos Corporation$343
  • plus $2K from 14 others

What the payments were for

  • Travel & lodging$97012%
  • Food & beverage$7,34188%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,336 in reported general payments places this provider in the 80th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$478,395
Medicare patients
867
Services billed
4,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate67$48,709
LumiganBimatoprost79$47,557
RestasisCyclosporine22$29,733
VyzultaLatanoprostene Bunod39$17,266
CombiganBrimonidine Tartrate/Timolol40$15,762
SimbrinzaBrinzolamide/Brimonidine Tart42$12,473
RocklatanNetarsudil Mesylat/Latanoprost23$11,685
Travoprost33$10,041
Brinzolamide39$7,423
Prednisolone Acetate130$7,181
Timolol Maleate150$5,828
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol36$5,718
Latanoprost395$5,678
TafluprostTafluprost/Pf20$5,132
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat198$4,209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$2,486$93,052141 claims
Bausch & Lomb Americas Inc.Vyzulta$218$17,26639 claims
AlconSimbrinza$2,031$12,47342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Chevy Chase

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →